Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease — PHOENIX

Sickle Cell Disease (SCD) Clinical Trial

Official title:
A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease

Status Active, not recruiting

Clinical Trial Summary

The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05565092
Study type	Interventional
Source	Alexion
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 22, 2023
Completion date	June 24, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03474965` - Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients	Phase 2
Active, not recruiting	`NCT03814746` - Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients	Phase 3
Completed	`NCT04662931` - An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients	Phase 4
Completed	`NCT03478917` - Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
Completed	`NCT03264989` - Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)	Phase 2
Completed	`NCT04053764` - Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease	Phase 2